Irsamla

Vortioxetine, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients. It is indicated for patients who require a novel approach to serotonin modulation.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Vortioxetine acts on the serotonergic system and is approved for the treatment of major depressive disorder.

Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients.

Vortioxetine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Headache - Dizziness - Dry mouth

Serious or Rare Side Effects: - Serotonin syndrome - Suicidal thoughts or behavior - Severe allergic reaction (anaphylaxis)

When prescribing Vortioxetine, clinicians should consider several safety precautions.

Monitor for worsening depression: assess suicidal ideation regularly. Assess hepatic function: dose adjustment may be needed in severe liver impairment. Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. Use with caution in the elderly: increased sensitivity to side effects. Store at room temperature: keep in the original container, protect from moisture.

Vortioxetine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs) within 14 days - Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid) - St. John’s wort - Strong CYP2D6 inhibitors

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol) - NSAIDs (increased bleeding risk) - Antihypertensive agents (possible blood pressure changes)